These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 27525443

  • 1. Why Biologic Therapies Sometimes Lose Efficacy.
    Strober BE.
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S78-80. PubMed ID: 27525443
    [Abstract] [Full Text] [Related]

  • 2. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [Abstract] [Full Text] [Related]

  • 3. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA, Krulig E, Gordon KB.
    Dermatol Ther; 2009 Apr; 22(5):431-40. PubMed ID: 19845720
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
    Farhangian ME, Feldman SR.
    Am J Clin Dermatol; 2015 Aug; 16(4):285-294. PubMed ID: 25963062
    [Abstract] [Full Text] [Related]

  • 5. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.
    Busard CI, Menting SP, van Bezooijen JS, van den Reek JM, Hutten BA, Prens EP, de Jong EM, van Doorn MB, Spuls PI.
    Trials; 2017 Feb 02; 18(1):52. PubMed ID: 28148280
    [Abstract] [Full Text] [Related]

  • 6. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J, Kerdel F.
    Dermatol Ther; 2008 Feb 02; 21(2):131-41. PubMed ID: 18394087
    [Abstract] [Full Text] [Related]

  • 7. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N, Nour T.
    Expert Opin Biol Ther; 2014 Jun 02; 14(6):749-56. PubMed ID: 24661040
    [Abstract] [Full Text] [Related]

  • 8. Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say?
    Jensen JD, Delcambre MR, Nguyen G, Sami N.
    Am J Clin Dermatol; 2014 Oct 02; 15(5):379-85. PubMed ID: 25027461
    [Abstract] [Full Text] [Related]

  • 9. Treatment of severe psoriasis.
    Puig L.
    J Eur Acad Dermatol Venereol; 2012 Aug 02; 26 Suppl 5():17-8. PubMed ID: 22758913
    [Abstract] [Full Text] [Related]

  • 10. Use of biologic agents in pediatric psoriasis.
    Marji JS, Marcus R, Moennich J, Mackay-Wiggan J.
    J Drugs Dermatol; 2010 Aug 02; 9(8):975-86. PubMed ID: 20684148
    [Abstract] [Full Text] [Related]

  • 11. Increase in antinuclear antibody levels through biologic treatment for psoriasis.
    Miki M, Endo C, Naka Y, Fukuya Y, Kobayashi S, Kawashima M, Tsunemi Y.
    J Dermatol; 2019 Feb 02; 46(2):e50-e51. PubMed ID: 30051919
    [No Abstract] [Full Text] [Related]

  • 12. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, Augustin M.
    Arch Dermatol Res; 2015 Dec 02; 307(10):875-83. PubMed ID: 26358263
    [Abstract] [Full Text] [Related]

  • 13. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM, Luber AJ, Levitt JO, Lebwohl MG.
    J Drugs Dermatol; 2013 Oct 02; 12(10):1098-102. PubMed ID: 24085044
    [Abstract] [Full Text] [Related]

  • 14. Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis.
    Chiu HY, Wang TS, Chan CC, Lin SJ, Tsai TF.
    Acta Derm Venereol; 2015 Jul 02; 95(6):711-6. PubMed ID: 25673333
    [Abstract] [Full Text] [Related]

  • 15. Identifying the biologic closest to the ideal to treat chronic plaque psoriasis in different clinical scenarios: using a pilot multi-attribute decision model as a decision-support aid.
    Guibal F, Iversen L, Puig L, Strohal R, Williams P.
    Curr Med Res Opin; 2009 Dec 02; 25(12):2835-43. PubMed ID: 19916728
    [Abstract] [Full Text] [Related]

  • 16. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L.
    Br J Dermatol; 2015 Jan 02; 172(1):244-52. PubMed ID: 25132294
    [Abstract] [Full Text] [Related]

  • 17. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
    Levine D, Strober BE.
    Semin Cutan Med Surg; 2010 Mar 02; 29(1):28-34. PubMed ID: 20430305
    [Abstract] [Full Text] [Related]

  • 18. Erythrodermic psoriasis: current and future role of biologicals.
    Stinco G, Errichetti E.
    BioDrugs; 2015 Apr 02; 29(2):91-101. PubMed ID: 25752640
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
    Qiang JK, Shahbaz A, Kim W, Marinas J, Greaves S, Yeung J.
    J Am Acad Dermatol; 2016 Jan 02; 74(1):176-7. PubMed ID: 26702799
    [No Abstract] [Full Text] [Related]

  • 20. Biologic treatments for elderly patients with psoriasis.
    Momose M, Asahina A, Hayashi M, Yanaba K, Umezawa Y, Nakagawa H.
    J Dermatol; 2017 Sep 02; 44(9):1020-1023. PubMed ID: 28439956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.